Investment

Company alerts ❯

• June 2, 2023
  Stealth BioTherapeutics

  Stealth BioTherapeutics (NAS: MITO)

  LT 2419

  419 of 880

  Stealth BioTherapeutics is a biopharmaceutical company dedicated to developing therapies addressing mitochondrial dysfunction in genetic mitochondrial diseases and age-related conditions. Their lead candidate, elamipretide, penetrates cell membranes and targets the inner mitochondrial membrane, enhancing mitochondrial respiration and function. This elamipretide-cardiolipin interaction improves mitochondrial structure and is being investigated for ophthalmic, neuromuscular, and cardiomyopathy disorders. Their second-generation candidate, SBT-272, targets neurological diseases like amyotrophic lateral sclerosis. Collaborating with patients and advocacy groups, Stealth aims to address unmet needs and raise awareness about mitochondrial disease.

  Longevity pillar

  • Treatment
  • Prevention

  Longevity domain:

  • Longevity drugs
  • Neuropharma
  • Discovery platforms

  Longevity target: Aging Driver, Aging Disease

  and Pharmanovia partner for commercialisation of elamipretide. Read more
• June 2, 2023
  Adiso Therapeutics

  ADISO therapeutics

  LT 2012

  12 of 880

  ADISO therapeutics creates novel therapies for inflammatory diseases. Current treatment paradigms are far too often either inadequate to halt disease progression or burden the patient with significant safety concerns. To tackle these challenges, ADISO therapeutics are advancing an innovative pipeline of multi-modal small molecules. ADS051, a pioneering oral, gut-restricted modulator, targets ulcerative colitis. Likewise, ADS032, a first-in-class small molecule, inhibits both NLRP3 & NLRP1 inflammasomes. In advanced pre-clinical development, it aims to address respiratory and dermal inflammation

  Longevity pillar

  • Prevention
  • Treatment

  Longevity domain:

  • Longevity immunity

  Longevity target: Aging Driver

  announces the completion of a phase 1b for the treatment of moderately-to-severely active ulcerative colitis. Read more
• June 1, 2023
  Seal Rock Therapeutics

  Seal Rock therapeutics

  LT 2394

  394 of 880

  Seal Rock Therapeutics is a clinical-stage biotech company dedicated to addressing organ injury, inflammation, and fibrosis caused by various factors. Their focus centers on small molecule inhibitors of ASK1 (apoptosis signal-regulating kinase 1). With SRT-015, a second-generation ASK1 inhibitor, they are targeting liver diseases through a trimodal therapeutic approach that demonstrates antifibrotic, anti-inflammatory, and anti-apoptotic effects. SRT-015 has successfully completed a phase 1 clinical trial, showcasing promising safety and efficacy. Additionally, Seal Rock Therapeutics has introduced SRT-055, a pioneering dual LRRK2/ASK1 inhibitor, aiming to treat central nervous system disorders such as Parkinson's disease. Their pipeline includes programs for alcoholic hepatitis, NASH, acute liver failure, Parkinson's, and ALS.

  Longevity pillar

  • Treatment
  • Prevention

  Longevity domain:

  • Longevity immunity
  • Discovery platforms
  • Neuropharma

  Longevity target: Aging Disease, Aging Driver

  announces out-licensing agreement with GENFIT. Read more
• May 31, 2023
  Humacyte

  Humacyte Inc.

  LT 2205

  205 of 880

  Humacyte is at the forefront of developing and producing universally implantable bioengineered human tissues. Their Humacyte Human Acellular Vessel (HAV) is an innovative regenerative vascular conduit undergoing clinical trials for various vascular applications such as trauma repair, hemodialysis access, and peripheral arterial disease. Beyond this, Humacyte envisions their platform technology as having the potential to address complex organ diseases, offering solutions like bioengineered replacement tissues and organs for procedures like coronary artery bypass grafts, pediatric heart surgery, and Type 1 diabetes treatment.

  Longevity pillar

  • Renewal
  • Treatment

  Longevity domain:

  • Regeneration

  Longevity target: Aging Disease

  grows human blood vessels and sends them to wounded Ukraine soldiers. Read more
• May 30, 2023
  Athersys

  Athersys (NAS: ATHX)

  LT 2048

  48 of 880

  Athersys is a leading biotechnology company specializing in the realm of regenerative medicine. Their unwavering dedication lies in creating therapeutic solutions that surpass current standards of safety and effectiveness, outperforming both existing care norms and contemporaneous developmental products. Central to Athersys' portfolio is MultiStem®, a revolutionary "off-the-shelf" stem cell therapy platform harnessed from adult sources. This innovation is tailored for an array of disease indications within the neurological, inflammatory & immune, and cardiovascular realms, as well as addressing crucial care gaps where current standards of treatment fall short.

  Longevity pillar

  • Treatment
  • Renewal

  Longevity domain:

  • Regeneration

  Longevity target: Aging Driver, Aging Disease

  files to sell 5.685mn shares of common stock for holders. Read more
• May 30, 2023
  Heartseed

  Heartseed

  LT 2202

  202 of 880

  Heartseed has established a mission focused on "facilitating heart disease treatment through regenerative medicine." Their efforts are dedicated to achieving the earliest feasible application of myocardial regenerative medicine. The organization is actively developing a treatment approach for heart failure, involving the creation of heart cells from induced pluripotent stem cells (iPS cells) and their subsequent transplantation into heart tissue. With substantial backing from numerous entities including companies, academic institutions, and the Japanese government, clinical trials for their flagship candidate, HS-001, are poised to commence shortly. Additionally, Heartseed is engaged in research endeavors aimed at making myocardial regenerative medicine a widespread practice, including investigations into advanced pipelines and streamlined iPS cell production methods.

  Longevity pillar

  • Renewal
  • Treatment

  Longevity domain:

  • Regeneration

  Longevity target: Aging Disease

  bags $14mn Series D. Read more